Physician profile
Anil George
NPI 1679639470
$12,256.52
in general payments reported to CMS, 2019-2025
53 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,335 · 2020: $1,414 · 2021: $2,354 · 2022: $2,189 · 2023: $2,095 · 2024: $1,693 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,965.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,705.14 | 2019-2025 | Lokelma, Breztri, Farxiga |
| Novo Nordisk INC | $992.77 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $816.33 | 2021-2025 | |
| Glaxosmithkline, LLC. | $718.77 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $667.57 | 2020-2025 | |
| Amgen INC. | $645.03 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Lilly USA, LLC | $611.56 | 2019-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $602.24 | 2019-2025 | |
| Amarin Pharma, INC. | $463.74 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $460.14 | 2019-2024 | Verquvo, Belsomra |
| Dexcom, INC. | $419.30 | 2022-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $330.11 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Astellas Pharma US INC | $314.16 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $247.82 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $231.84 | 2019-2024 | Xarelto |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.